Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-02-06
2000-05-30
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514560, A61K 3134, A61K 3120
Patent
active
060691689
ABSTRACT:
Use of 6-desaturated n-6 fatty acids, especially gammalinolenic acid (GLA), dihomogammalinolenic acid (DGLA) or arachidonic acid (AA), together with a pharmaceutically acceptable material reducing intracellular levels of sorbitol in the body, particularly an aldose reductase inhibitor, in the treatment of (including prophylactic treatment), and in the preparation of medicaments for the treatment of (including prophylactic treatment), the long-term complications of diabetes mellitus. Pharmaceutical compositions of said materials. The ascorbate esters of 6-desaturated n-6 fatty acids (other than GLA or DGLA) per se.
REFERENCES:
patent: 4388324 (1983-06-01), Horrobin
patent: 4826877 (1989-05-01), Stewart et al.
patent: 5009891 (1991-04-01), Niwa et al.
patent: 5078989 (1992-01-01), Ando et al.
patent: 5114716 (1992-05-01), N'Guyen et al.
patent: 5278189 (1994-01-01), Rath et al.
Horrobin, Agents Actions (Switzerland), 37/suppl., pp. 120-144, 1992.
Stracke et al.,, Innere Medizin, 48, pp.259-261, 1993.
Gen Pharmacol, vol. 21, No. 1, pp. 135-140, 1990; Law et al: "Effects of Ponalrestat on Depressor Responses to Arachidonic Acid in Streptozoticon-diabetic Rats," (p. 138, col. 2, line 10-line 29).
Nervenheilkunde (Germany), 1993, vol. 12, No. 7, pp. 405-410; Ziegler et al: "Diabetische Neuropathie: Pathogenetische Konzepte Und Potentielle Therapeutische Konsequenzen"; p. 406, col. 2, line 39-60; page 407, col. 3, line 8-22.
Dtsch. Med. Wochenschr. (Germany, Federal Republic of), 1991, vol. 116, No. 18, pp. 716-717; Ziegler et al: "Pain treatment in diabetic polyneuropathy"; p. 716, col. 2, line 25-49.
Diabetic Med. (United Kingdom), 1993, vol. 10, Suppl. 2, pp. 4S-6S; Ward: "Progress and Treatment in Diabetic Neuropathy"; p. 55, col. 2, line 13-15.
Patent Abstracts of Japan, C field, vol. 11, No. 282 Sep. 1987 p 103 C 446 JP 62-81 307 Kanebo.
Chem. Abs. vol. 107, 1987 83706m p. 33707 Kanebo.
Patent Abstract of Japan 06093284 A Apr. 94 Hiroshi et al Highly Stable Perilla Oil and Cosmetic Base Material Contianing the Perilla Oil as Active Ingredient.
Garrison et al. "The Nutrition Desk Reference", published by Keating Publishing, Inc., pp. 95 and 96, 1985.
Embase abstract of Horrobin, "The use of gamma-linolenic acid in diabetic neuropathy", Agents Actions (Switzerland), 37/suppl. (120144) 1992.
Embase abstract of Stracke et al., "Diagnosis and therapy of diabetic polyneurpathy" Z Gesamte Inn Med (Germany), 48(5) pp. 259-261, 1993.
Martindale 28th Edition, p. 1653 (Jul. 23, 1985).
USP 21st Edition, pp. 75-76 (Jun. 24 1986).
The Merck Index, 10th Edition, p. 120 (1993.
Cameron Norman
Cotter Mary
Horrobin David Frederick
Henley III Raymond
Scotia Holdings PLC
LandOfFree
Compositions for treatment of diabetic complications does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for treatment of diabetic complications, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for treatment of diabetic complications will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1910732